Tempus M&A Wednesday, November 18, 2026 +0.50 Positive

AstraZeneca extends multi-year Oncology Data Alliance

Tempus AI and AstraZeneca have finalized a Fifth Amendment to extend their strategic oncology collaboration through the Renewal Term starting January 1, 2027. This secures continued cooperation in drug discovery, data integration, and clinical operations.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed